未手术的潜在可治愈局限期胃腺癌放化疗结局
该回顾性队列纳入71例未手术的局限期胃腺癌患者,接受化疗和/或放化疗。中位随访1.8年,中位OS为2.1年(95%CI 1.78-2.55),2年和5年OS率分别为54%和18%;32例(45.1%)达临床完全缓解。多因素分析显示女性及放化疗与更长OS独立相关。
要点
- 未手术局限期胃腺癌放化疗后5年OS率为18%,中位OS 2.1年
- 50例可评估再分期患者中32例(45.1%)达临床完全缓解
- 女性及接受放化疗与更长OS独立相关
核心结论
- 未接受手术的局限期胃腺癌患者接受化疗和/或放化疗后,5年OS率为18%。
研究设计与样本
- 回顾性队列研究,纳入71例未手术的局限期胃腺癌患者,接受化疗和/或放化疗。
主要发现
- 中位随访1.8年(范围0.4-10.6),男性占64.8%,中位年龄73岁(范围30-96)。
- 未手术原因包括合并症34例(47.9%)、体能状态差14例(19.7%)、患者拒绝23例(32.4%)。
- 50例可完成内镜和影像再分期评估,其中32例(45.1%)达临床完全缓解(cCR)。
- 全队列中位OS为2.1年(95%CI 1.78-2.55),2年和5年OS率分别为54%和18%。
- 多因素分析中,女性(HR 0.39,95%CI 0.16-0.98,p=0.045)和放化疗(HR 0.25,95%CI 0.06-1.01;p=0.05)与更长OS独立相关。
临床怎么用
- 对于因合并症、体能状态差或患者拒绝而无法手术的局限期胃腺癌,可考虑化疗和/或放化疗作为替代治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgery is the best option for cure of localised gastric adenocarcinoma (GAC). When surgery is not possible due to comorbidities or patient choice, definitive chemoradiation is an option. We report on one of the largest cohorts of localised GAC patients who did not have surgery. METHODS: We identified 71 patients with localised GAC who received chemo/chemoradiation therapy but did not have surgery. We assessed various end-points: overall survival (OS), relapse-free survival (RFS), and clinical complete response (cCR; negative post therapy biopsy and no evidence of cancer by imaging). RESULTS: The median follow-up time was 1.8 years (range; 0.4-10.6). Most of the patients were men (64.8%), and the median age was 73 years (range; 30-96). Reason for not having surgery included comorbidities in 34 (47.9%), poor performance status 14 (19.7%), and patient refusal 23 (32.4%). Of all 71 patients, a complete restaging evaluation with endoscopy and imaging could be performed for 50, and 32 (45.1%) achieved a cCR. For the entire cohort, the median OS was 2.1 years (95% confidence interval [CI] 1.78-2.55). The estimated OS rates at 2 and 5 years were 54% and 18%, respectively. Female gender (HR 0.39, 95% CI 0.16-0.98, p = 0.045) and chemoradiation (HR 0.25, 95% CI 0.06-1.01; p = 0.05) were independently associated with longer OS in the multivariate analysis. CONCLUSION: Our data show that patients with localised GAC treated with chemotherapy and/or chemoradiation, who do not undergo surgery, have a 5-year OS rate of 18%.
引用
- Mizrak Kaya D, Nogueras-Gonzáles GM, Harada K, et al. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018. PMID: 29859338. doi:10.1016/j.ejca.2018.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。